Faeth Therapeutics
FTH
Categories
Founded
2022
Leadership
- Anand Parikh, JD, Co-Founder and CEO
Headquarters
San Francisco, CA
Website
S2G North Star Interim Outcomes
- Increased availability, accessibility, and/or affordability of healthier foods and nutrition-based solutions Jump to footnote 1
Faeth Therapeutics is a clinical-stage biotechnology company focused on improving outcomes for cancer patients.
The company’s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
Insights
News
Inside Precision Medicine
Faeth Therapeutics Proves Three-Pronged Approach to Cancer, Preclinically
Footnotes
S2G North Star Interim Outcomes reflect areas of strategic alignment with our long-term impact goals. These outcomes are intended to illustrate the types of non-financial progress S2G seeks to support across its portfolio and do not represent company-specific metrics or outcomes. They are not a reflection of investment performance, actual or realized returns, or future financial results.